Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RSG XR
RSG · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment Arm AB | EXPERIMENTAL | A will be a single tablet RSG XR 8 milligram (mg) manufactured in Harlow administered in the fasted state and B will be a single tablet RSG XR 8 mg manufactured in Crawley administered in the fasted state. In Arm AB subject will receive A regimen in Period 1 and B regimen in Period 2.There will be wash-out period of 5 days between doses. |
| Treatment Arm BA | EXPERIMENTAL | A will be a single tablet RSG XR 8 mg manufactured in Harlow administered in the fasted state and B will be a single tablet RSG XR 8 mg manufactured in Crawley administered in the fasted state. In Arm BA subject will receive B regimen in Period 1 and A regimen in Period 2. There will be wash-out period of 5 days between doses. |
| Name | Type | Description |
|---|---|---|
| RSG XR | DRUG | RSG XR tablets 8 mg enteric-coated tablet formulation consisting of 3mg fast release plus 5mg slow release. Subject will receive one 8mg of RSG XR on each dosing day. The subject will receive a single oral dose of regiment A or B with 240 milliliter (mL) of water. |
Inclusion Criteria: * Healthy male or female aged 18-55 years. * BMI between 19 - 30 kg/m2 Exclusion criteria: * Liver function tests above the upper limit * Excessive alcohol consumption history * History of Cigarette smoking * Positive HIV, Hep B or C test * Positive pregnancy test * History of...
Top 20 of 30 competitors
RSG is an investigational small molecule developed by GSK plc for Alzheimer's Disease. It is also known as RSG XR. The program is in Phase 1 clinical development, and the one recorded trial has been completed. RSG has not been approved for any use based on the available development information.
RSG is being studied for Alzheimer's Disease, a neurology indication. Development is at Phase 1, the earliest stage of clinical testing, so RSG is investigational and is not an approved treatment for Alzheimer's Disease or any other condition.
RSG is developed by GSK plc, which trades under the ticker GSK. The company is the sponsor behind the RSG XR program in Alzheimer's Disease, which has reached Phase 1 testing.
RSG is in Phase 1 clinical development. One trial has been completed and no trials are currently active. Because it remains in early-stage testing, RSG is investigational and has not been approved by the FDA or any other regulator for Alzheimer's Disease.
RSG has been evaluated in one completed Phase 1 trial, NCT00468897, titled a study to demonstrate the bioequivalence of Rosiglitazone XR (BRL-049653) 8 mgs XR manufactured at two different sites. That trial enrolled 50 participants in Germany, was randomized and controlled, and included healthy volunteers.
Yes, RSG XR is an alternative name for RSG, the GSK plc small molecule being studied in Alzheimer's Disease. The completed Phase 1 trial NCT00468897 refers to the drug as Rosiglitazone XR, or BRL-049653, which is the same asset.